Baricitinib Decreases Anti-dsDNA and IgG Antibodies in Adults with Systemic Lupus Erythematosus from a Phase 2 Double-Blind, Randomized, Placebo-Controlled Trial

被引：0
|
作者：
Doerner, Thomas [1 ,2 ]
Van Vollenhaven, Ronald [3 ]
Doria, Andrea [4 ]
Jia, Bochao [5 ]
Fantini, Damiano [5 ]
Terres, Jorge Ross [5 ]
Silk, Maria [6 ]
de Bono, Stephanie [5 ]
Fischer, Peter [7 ]
Wallace, Daniel [8 ]
机构：
[1] Charite Univ Med Berlin, Berlin, Germany
[2] Deutsch Rheumaforschungszentrum DRFZ, Berlin, Germany
[3] Univ Med Ctr, Amsterdam, Netherlands
[4] Univ Padua, Padua, Italy
[5] Eli Lilly & Co, Indianapolis, IN USA
[6] Eli Lilly & Co, Carmel, IN USA
[7] Eli Lilly & Co, N Easton, MA USA
[8] Cedars Sinai, Los Angeles, CA USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2021年 / 73卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1746
引用
收藏
页码：3640 / 3642
页数：3
相关论文
共 50 条
  • [1] BARICITINIB DECREASES ANTI-DSDNA AND IGG ANTIBODIES IN ADULTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS FROM A PHASE 2 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL
    Maney, Nicola
    Doerner, Thomas
    van Vollenhoven, Ronald F.
    Doria, Andrea
    Jia, Bochao
    Fantini, Damiano
    Terres, Jorge A. Ross
    Silk, Maria E.
    de Bono, Stephanie
    Fischer, Peter
    Wallace, Daniel J.
    [J]. RHEUMATOLOGY, 2022, 61 : I131 - I131
  • [2] BARICITINIB DECREASES ANTI-DSDNA AND IGG ANTIBODIES IN ADULTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS FROM A PHASE 2 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL
    Doerner, T.
    Van Vollenhoven, R.
    Doria, A.
    Jia, B.
    Fantini, D.
    Terres, J. Ross
    Silk, M.
    De Bono, S.
    Fischer, P.
    Wallace, D. J.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 588 - 589
  • [3] Baricitinib decreases anti-dsDNA in patients with systemic lupus erythematosus: results from a phase II double-blind, randomized, placebo-controlled trial
    Doerner, Thomas
    van Vollenhoven, Ronald F.
    Doria, Andrea
    Jia, Bochao
    Terres, Jorge A. Ross
    Silk, Maria E.
    de Bono, Stephanie
    Fischer, Peter
    Wallace, Daniel J.
    [J]. ARTHRITIS RESEARCH & THERAPY, 2022, 24 (01)
  • [4] Baricitinib decreases anti-dsDNA in patients with systemic lupus erythematosus: results from a phase II double-blind, randomized, placebo-controlled trial
    Thomas Dörner
    Ronald F. van Vollenhoven
    Andrea Doria
    Bochao Jia
    Jorge A. Ross Terres
    Maria E. Silk
    Stephanie de Bono
    Peter Fischer
    Daniel J. Wallace
    [J]. Arthritis Research & Therapy, 24
  • [5] Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial
    Wallace, Daniel J.
    Furie, Richard A.
    Tanaka, Yoshiya
    Kalunian, Kenneth C.
    Mosca, Marta
    Petri, Michelle A.
    Doerner, Thomas
    Cardiel, Mario H.
    Bruce, Ian N.
    Gomez, Elisa
    Carmack, Tara
    DeLozier, Amy M.
    Janes, Jonathan M.
    Linnik, Matthew D.
    de Bono, Stephanie
    Silk, Maria E.
    Hoffman, Robert W.
    [J]. LANCET, 2018, 392 (10143): : 222 - 231
  • [6] Baricitinib in Patients with Systemic Lupus Erythematosus: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
    Wallace, Daniel J.
    Furie, Richard
    Tanaka, Yoshiya
    Kalunian, Kenneth C.
    Mosca, Marta
    Petri, Michelle
    Dorner, Thomas
    Cardiel, Mario H.
    Bruce, Ian N.
    Gomez, Elisa
    DeLozier, Amy M.
    Janes, Jonathan
    Linnik, Matthew D.
    de Bono, Stephanie
    Silk, Maria E.
    Hoffman, Robert W.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [7] Memantine in Systemic Lupus Erythematosus: A Randomized, Double-Blind Placebo-Controlled Trial
    Petri, Michelle
    Naqibuddin, Mohammad
    Sampedro, Margaret
    Omdal, Roald
    Carson, Kathryn A.
    [J]. SEMINARS IN ARTHRITIS AND RHEUMATISM, 2011, 41 (02) : 194 - 202
  • [8] BARICITINIB IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): RESULTS FROM A PHASE 2, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
    Wallace, D. J.
    Furie, R. A.
    Tanaka, Y.
    Kalunian, K. C.
    Mosca, M.
    Petri, M. A.
    Dorner, T.
    Cardiel, M. H.
    Bruce, I. N.
    Gomez, E.
    Carmack, T.
    Janes, J. M.
    Linnik, M. D.
    Silk, M.
    Hoffman, R.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 59 - 59
  • [9] A double-blind, randomized, placebo-controlled, phase II trial of baricitinib for systemic lupus erythematosus: how to optimize lupus trials to examine effects on cutaneous lupus erythematosus
    Werth, V. P.
    Merrill, J. T.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2019, 180 (05) : 964 - 965
  • [10] Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial (vol 392, pg 222, 2018)
    Wallace, D. J.
    Furie, R. A.
    Tanaka, Y.
    [J]. LANCET, 2018, 392 (10146): : 476 - 476
12345